Prognosis after cryptogenic cerebral ischemia in patients with coagulopathies

Cerebrovascular Diseases

Volumn 28, Issue 6, 2009, Pages 611-617

  Weber, Ralph ^a   Goertler, Michael ^b   Benemann, Jens ^a   Diener, Hans Christoph ^a   Weimar, Christian ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Anticoagulation; Antiplatelet agents; Coagulopathy; Cryptogenic cerebral ischemia

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN III; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PROTEIN C; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ANTICOAGULATION; ANTITHROMBIN III DEFICIENCY; ARTICLE; BLOOD CLOTTING DISORDER; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN C DEFICIENCY; RECURRENCE RISK; RECURRENT DISEASE; SECONDARY PREVENTION; TRANSIENT ISCHEMIC ATTACK;

ADULT; ANTICOAGULANTS; BLOOD COAGULATION DISORDERS, INHERITED; BRAIN ISCHEMIA; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; ISCHEMIC ATTACK, TRANSIENT; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 70350141952     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000251172     Document Type: Article

References (23)

1. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. Stroke 2006; 37: 577-617.
2. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW: Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166: 729-736.
3. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE: Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401S-428S.
4. Ost D, Tepper J, Mihara H, Lander O, Heinzer R, Fein A: Duration of anticoagulation following venous thromboembolism: a metaanalysis. JAMA 2005; 294: 706-715.
5. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, Murphy A, Lu Y, Costigan TM, Rhine C, Levin B, Triplett DA, Mohr JP: Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-584.
6. Bushnell CD, Goldstein LB: Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke 2000; 31: 3067-3078.
7. Hankey GJ, Eikelboom JW: Editorial comment - routine thrombophilia testing in stroke patients is unjustified. Stroke 2003; 34: 1826-1827.
8. Rahemtullah A, Van Cott EM: Hypercoagulation testing in ischemic stroke. Arch Pathol Lab Med 2007; 131: 890-901.
9. Fields MC, Levine SR: Thrombophilias and stroke: diagnosis, treatment, and prognosis. J Thromb Thrombolysis 2005; 20: 113-126.
10. Weimar C, Holle DN, Benemann J, Schmid E, Schminke U, Haberl RL, Diener HC, Goertler M: Current management and risk of recurrent stroke in cerebrovascular patients with cardiac right-to left-shunt. Cerebrovasc Dis 2009; 28: 349-356.
11. Spannagl M, Dick A, Reinauer H: External quality assessment schemes in coagulation in Germany: between regulatory bodies and patient outcome. Semin Thromb Hemost 2007; 33: 259-264.
12. Bushnell C, Siddiqi Z, Morgenlander JC, Goldstein LB: Use of specialized coagulation testing in the evaluation of patients with acute ischemic stroke. Neurology 2001; 56: 624-627. (Pubitemid 32209996)
13. Bushnell CD, Goldstein LB: Physician knowledge and practices in the evaluation of coagulopathies in stroke patients. Stroke 2002; 33: 948-953.
14. Botto N, Spadoni I, Giusti S, Ait-Ali L, Sicari R, Andreassi MG: Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale. Stroke 2007; 38: 2070-2073.
15. Slooter AJ, Rosendaal FR, Tanis BC, Kemmeren JM, Van der Graaf Y, Algra A: Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost 2005; 3: 1213-1217.
16. Pezzini A, Grassi M, Iacoviello L, Del Zotto E, Archetti S, Giossi A, Padovani A: Inherited thrombophilia and stratification of ischaemic stroke risk among users of oral contraceptives. J Neurol Neurosurg Psychiatry 2007; 78: 271-276.
17. Kluft C, Lansink M: Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78: 315-326.
18. Haapaniemi E, Helenius J, Jakovljevic D, Soinne L, Syrjälä M, Kaste M, Lassila R, Tatlisumak T: Ischaemic stroke patients with heterozygous factor V Leiden present with multiple brain infarctions and widespread atherothrombotic disease. Thromb Haemost 2009; 101: 145-150.
19. Strater R, Becker S, von Eckardstein A, Heinecke A, Gutsche S, Junker R, Kurnik K, Schobess R, Nowak-Gottl U: Prospective assessment of risk factors for recurrent stroke during childhood - a 5-year follow-up study. Lancet 2002; 360: 1540-1545.
20. Pruissen DM, Kappelle LJ, Algra A: Polymorphisms and Risk of Ischemic Stroke (POLARIS) study: rationale and design. Eur Neurol 2004; 51: 30-34.
21. De Moerloose P, Boehlen F: Inherited thrombophilia in arterial disease: a selective review. Semin Hematol 2007; 44: 106-113.
22. Douay X, Lucas C, Caron C, Goudemand J, Leys D: Antithrombin, protein c and protein s levels in 127 consecutive young adults with ischemic stroke. Acta Neurol Scand 1998; 98: 124-127.
23. Munts AG, Van Genderen PJ, Dippel DW, Van Kooten F, Koudstaal PJ: Coagulation disorders in young adults with acute cerebral ischaemia. J Neurol 1998; 245: 21-25.